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formally evaluate the validity of the screens with regards
to their ability to correctly identify ADEs. Validity was
expressed as positive predictive value (PPV).
RESULTS: Ten studies published between 1992 and 2000
met the inclusion criteria. Three approaches used to
measure ADE incidence were identiﬁed. Two studies
screened for generic adverse outcomes (e.g., inpatient
deaths), the average PPVs were 1% and 17.4%. Five
studies exclusively screened for surrogate outcomes (anti-
dotes commonly used to treat ADEs, or critical lab values,
such as elevated creatinine or drug levels) to predict the
occurrence of an ADE, with PPVs of 9, 12, 13, 18 and
37%. Three studies tested screens that combined med-
ications and intermediate outcomes (PPVs 12.4, 45 and
53%).
CONCLUSIONS: Automated health care data screens
show promise as ADE incidence measure. Their current
validity, however, does not appear to be sufﬁcient for
cross-sectional comparisons or the evaluation of quality
improvement initiatives. Increasing sophistication of the
screens by including multiple variables that link process
components (e.g. medication) along with adverse out-
comes or surrogates (e.g. lab values, antidotes) appear to
increase screen validity.
MENTAL HEALTH (including Alzheimer’s Disease,
Dementia,Alcoholism, and Attention Deﬁcit
Disorder)—Clinical Outcomes Presentations
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USEFULNESS OF ELECTRONIC COMPLIANCE
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OBJECTIVE: Effectiveness trials are designed to evaluate
patients in their natural setting with fewer constraints
than in efﬁcacy trials. The less-structured environ-
ment can result in a failed trial if participant activity is
unknown. We prepared for this possibility by including
electronic monitoring of medication dosing in a multi-
center trial.
METHODS: The trial was designed to assess the effec-
tiveness of naltrexone for the treatment of chronic 
alcoholism. Patients took either naltrexone or placebo
once daily, using MEMS caps (APREX, Union City, CA)
on their medication bottles to record the date and time
of each opening. We planned analyses by intention-
to-treat and covarying compliance as continuous and cat-
egorical variables (grouped as taking medication during
0–24%, 25–49%, 50–74%, >75% of weeks).
RESULTS: Primary endpoints showed no differences
between treatment groups at 3 months. Electronic moni-
toring revealed that patients took 72 + 31% of naltrex-
one and 70 + 31% of placebo doses (overall compliance
rates). Naltrexone was taken by 13%, 11%, 12%, and
65% of patients by category. Placebo was taken by 14%,
14%, 11%, and 61% of patients by category. Compliance
rates were not signiﬁcantly different overall or by cate-
gory between treatment groups. Planned secondary analy-
ses demonstrated that compliance was a predictor of
success (p = 0.03 for drinks/day), with no interaction for
treatment.
CONCLUSION: These data demonstrate the value of
electronic compliance measurement that provided data on
any period needed for analyses. Without these data, the
results of a complex and expensive study would have been
questioned. Critics could have charged that compliance
rates differed among treatment groups, or that inadequate
amounts of medication were taken to assess outcomes.
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The prognosis for patients with Alzheimer’s disease is
important information for physicians to be able to
provide patients and their relatives as an aid to making
appropriate arrangements before the severe stage is
reached.
OBJECTIVES: To provide prognosis aids for patients
with mild or moderate Alzheimer’s disease based on the
standardised Mini-Mental State Examination (SMMSE).
METHODS: Data from a Canadian cohort study of 206
patients with an initial SMMSE between 10 and 24 were
used to ﬁnd determinants of the three year probability of
reaching a highly dependent stage, deﬁned as SMMSE
<10. The regression equations were also used to derive a
reference failure-time curve. The predicted progression
was compared with that observed in a US study (N =
597).
RESULTS: Proportional hazards analyses showed that at
the mild stage (SMMSE 19 to 24) the presence of hallu-
cinations was associated with a more rapid decline,
whereas at the moderate stage (SMMSE 10 to 18) the
important predictors of decline were a lower baseline
SMMSE score and longer time since onset. Absence of
hallucinations in patients with an SMMSE above 18,
implied a 79% probability of remaining independent after
three years; presence of hallucinations reduced this to
52%, while a prior rate of decline of 2 points/year did so
even further to 43%. Less than half of patients whose
SMMSE was already below 19 and who had symptoms
for ﬁve years or longer remained independent after three
years. An initial score below 14 resulted in a probability
below 30%. The predictions based on the Canadian study
showed reasonable agreement with the progression
observed in the US study.
CONCLUSIONS: These equations permit estimation of
the expected progression of Alzheimer’s disease, and will
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aid clinicians when advising patients and their caregivers
about prognosis and treatment.
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OBJECTIVES: To assess the risk of diabetes among
patients undergoing treatment with risperidone vs.
haloperidol. A series of case reports had associated some
antipsychotic agents with diabetes.
METHODS: Patients with at least one prescription 
for either haloperidol or risperidone between January
1997 and 31st December 1999 recorded in the Regie de
l’Assurance Maladie de Quebec database, excluding 
those dispensed clozapine or olanzapine during the study
period or diagnosed with diabetes (deﬁned as either a
recorded ICD9 250.0 to 250.93 or a prescription for
insulin or an oral hypoglycemic agent) before beginning
anti-psychotic therapy, were divided into haloperidol
recipients (N = 14,602) and those receiving risperidone
but not haloperidol (N = 9,961). New diabetes diagnoses
after the ﬁrst antipsychotic prescription were tabulated;
censoring at study end or the last service date if there was
no record of using any services during the last six months
of follow-up. Crude hazard ratios and proportional
hazards analyses were carried out.
RESULTS: 406 patients developed diabetes after being
prescribed haloperidol, and 123 after risperidone, a crude
hazard ratio of 2.29 (95% CI 1.81–2.90). When correct-
ing for imbalances in age, and gender, using proportional
hazards analysis, haloperidol still increased the risk of
diabetes by 93% (HR = 1.93, 95% CI 1.57–2.37, 
P < 0.0001). Correction for other imbalances did not
change the ﬁndings.
CONCLUSIONS: Haloperidol was associated with an
increased risk of developing diabetes compared to risperi-
done. Additional studies are required to identify a bio-
logical basis for this association, and to examine other
atypical antipsychotics to determine which have the
lowest risk of diabetes.
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OBJECTIVE: To assess whether a 5-factor instead of 
3-factor model more completely describes the range of
psychotic symptoms as measured by the Positive and Neg-
ative Syndrome Scale (PANSS) with data from the Que-
tiapine Experience with Safety and Tolerability (QUEST)
trial, and to reevaluate the comparative efﬁcacy of queti-
apine and risperidone using the 5-symptom model.
METHODS: We used exploratory factor analysis (EFA)
to test whether three factors adequately describe symp-
toms as measured by the PANSS or if more factors are
needed. The initial EFA is carried out using only baseline
data. Evaluating the test for breaks in eigen values deter-
mines the number of factors. We used the n-factor rule to
retain and rotate enough factors to explain 99% of the
variation. Using the derived factorial structure, we per-
formed comparative analyses on the intent-to-treat (ITT)
population and on patients with clinically signiﬁcant
baseline symptoms (CSBS) at 2 and 4 months.
RESULTS: 554 patients had completed PANSS data; 
5 factors explained 99.9% of data variance and labeled
negative, positive, activation, dysphoria, and autistic pre-
occupation symptoms with corresponding eigen values
28.97, 7.55, 3.59, 2.63 and 1.45 explaining 66%, 17%,
8%, 6%, and 3% of the variation. Statistical analyses
found that, compared with risperidone, quetiapine con-
sistently improves dysphoria sooner and in patients with
CSBS. At 2 months quetiapine-treated patients’ absolute
change from baseline was -3.11 compared to -2.22 (P =
0.03). For patients with clinically signiﬁcant baseline 
negative symptoms, at 2-months the comparative change
in dsyphoria was -3.79 vs. -2.34 (P = 0.02). In patients
with clinically signiﬁcant positive symptoms, quetiapine
improved dsyphoria symptoms better than risperidone at
2 and 4-months, -4.06 vs. -2.24 (P = 0.01) and -4.73 vs.
-2.88 (P = 0.03).
CONCLUSIONS: PANSS is more completely described
with ﬁve symptoms. Compared with risperidone, queti-
apine displays clinical advantage in improving dysphoria
not evident when a 3-factor model is used.
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OBJECTIVES: Because clinical outcomes depression
treatment in primary care settings tend to be poor, we
developed and evaluated the efﬁcacy of two augmenta-
tions to antidepressant treatment to be delivered by
primary care nurses.
METHODS: We conducted a randomized trial compar-
ing usual care, telehealth care, and telehealth care plus
peer support for depressed patients seen in primary care
in an HMO setting. Assessments were conducted at base-
line, 6 weeks and 6 months after study enrollment at two
managed care adult primary care clinics. Participants
were 303 patients recently started on antidepressants. The
intervention consisted of: telehealth care; emotional
